A new position paper from noted thought leaders and the Association of Clinical Research Professionals provides the much-needed voice of the clinical trial professional.
After months of investigation, the U.S. Food and Drug Administration will not bring any penalties against Novartis over the data manipulation of the gene therapy Zolgensma, a multi-million dollar treatment for spinal muscular atrophy.
